Clinical utility of micafungin: Pharmacokinetics, dosing, use in special populations and drug interactions

Mycoses

Volumn 55, Issue SUPPL.1, 2012, Pages 33-38

  Hope, W W ^a   Howard, S J ^a   Felton, T W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Antifungal; Aspergillus; Candida; Echinocandin; Micafungin; Pharmacokinetics

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; CREATININE; CYCLOSPORIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; MYCOPHENOLIC ACID; NIFEDIPINE; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; VORICONAZOLE;

AREA UNDER THE CURVE; ARTICLE; CANDIDIASIS; CREATININE CLEARANCE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG POTENTIATION; DRUG STRUCTURE; HEMODIALYSIS; HEMOLYSIS; HEPATITIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER FAILURE; LIVER FUNCTION TEST; MAXIMUM TOLERATED DOSE; OSTEOMYELITIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE;

ASPERGILLUS; CANDIDA;

EID: 84859410881     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2011.02114.x     Document Type: Article

References (41)

1. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-51.
2. Petraitis V, Petraitiene R, Groll AH et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46: 1857-69.
3. Denning DW, Marr KA, Lau WM et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53: 337-49.
4. Pappas PG, Rotstein CM, Betts RF et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93.
5. Barrett D. From natural products to clinically useful antifungals. Biochim Biophys Acta 2002; 1587: 224-33.
6. Astellas P. Highlights of prescribing information.
7. Hebert MF, Smith HE, Marbury TC et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 2005; 45: 1145-52.
8. Gumbo T, Hiemenz J, Ma L, Keirns JJ, Buell DN, Drusano GL. Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis 2008; 60: 329-31.
9. Hope WW, Seibel NL, Schwartz CL et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 2007; 51: 3714-9.
10. Hope WW, Smith PB, Arrieta A et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2007; 54: 2633-7.
11. Groll AH, Mickiene D, Petraitis V et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 2001; 45: 3322-7.
12. Hope WW, Mickiene D, Petraitis V et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008; 197: 163-71.
13. Benjamin DK Jr, Smith PB, Arrieta A et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 2001; 87: 93-99.
14. Smith PB, Walsh TJ, Hope W et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 2009; 28: 412-5.
15. Nicasio AM, Tessier PR, Nicolau DP et al. Bronchopulmonary disposition of micafungin in healthy adult volunteers. Antimicrob Agents Chemother 2009; 53: 1218-20.
16. Walsh TJ, Goutelle S, Jelliffe RW et al. Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients. Antimicrob Agents Chemother 2010; 54: 3451-9.
17. van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-16.
18. Lat A, Thompson GR 3rd, Rinaldi MG, Dorsey SA, Pennick G, Lewis JS 2nd. Micafungin concentrations from brain tissue and pancreatic pseudocyst fluid. Antimicrob Agents Chemother 2010; 54: 943-4.
19. Yamada N, Kumada K, Kishino S, Mochizuki N, Ohno K, Ogura S. Distribution of micafungin in the tissue fluids of patients with invasive fungal infections. J Infect Chemother 2011; 17: 731-4.
20. Mochizuki K, Suemori S, Udo K et al. Intraocular penetration of micafungin in patient with Candida albicans endophthalmitis. J Ocul Pharmacol Ther 2011; 27: 531-3.
21. Sobel JD, Bradshaw SK, Lipka CJ, Kartsonis NA. Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis 2007; 44: e46-49.
22. Andes DR, Diekema DJ, Pfaller MA, Marchillo K, Bohrmueller J. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008; 52: 3497-503.
23. Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005; 49: 5058-68.
24. Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 2010; 54: 2497-506.
25. Howard SJ, Slater J, Sharp A et al. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. Antimicrob Agents Chemother 2011; 55: 4880-7.
26. Park S, Kelly R, Kahn JN et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005; 49: 3264-73.
27. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010; 48: 2373-80.
28. Slater JL, Howard SJ, Sharp A et al. Disseminated candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob Agents Chemother 2011; 55: 3075-83.
29. Hiemenz J, Cagnoni P, Simpson D et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005; 49: 1331-6.
30. Sirohi B, Powles RL, Chopra R et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 38: 47-51.
31. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
32. Heresi GP, Gerstmann DR, Reed MD et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006; 25: 1110-5.
33. Seibel NL, Schwartz C, Arrieta A et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005; 49: 3317-24.
34. Gumbo T, Drusano GL, Liu W et al. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 2007; 51: 968-74.
35. Mehta PA, Vinks AA, Filipovich A et al. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant 2010; 16: 1458-62.
36. Hebert MF, Townsend RW, Austin S et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45: 954-60.
37. Hebert MF, Blough DK, Townsend RW et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005; 45: 1018-24.
38. Fukuoka N, Imataki O, Ohnishi H et al. Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation. Transplant Proc 2010; 42: 2725-30.
39. Petraitis V, Petraitiene R, Sarafandi AA et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187: 1834-43.
40. Keirns J, Sawamoto T, Holum M, Buell D, Wisemandle W, Alak A. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. Antimicrob Agents Chemother 2007; 51: 787-90.
41. Krishna G, Vickery D, Ma L et al. Lack of Pharmacokinetic Drug Interaction Between Oral Posaconazole and Caspofungin or Micafungin. J Clin Pharmacol 2011; 51: 84-92.